Getting the right data to doctors is next hurdle for precision medicine
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
AltheaDx secures $30M Series C for its IDgenetix testing
AltheaDx has raised significant funds to further its personalized medicine platform led by WuXi Healthcare Ventures.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mayo Clinic’s Farrugia on the future of precision medicine: Patients are ready to engage
Gianrico Farrugia keynoted this week's Individualizing Medicine Conference at Mayo Clinic with a talk on what to expect in the immediate future of precision medicine.
CONVERGE: Population medicine has been a spectacular failure, but payers are hindering innovation
Susan Hertzberg, Boston Heart Diagnostics CEO said although genomic sequencing holds a lot of promise beyond cancer treatment, "right here, right now, we have not optimized or used fully what's available."
GuardantHealth, Flatiron Health to link genomics, analytics for personalized cancer care
In a further sign of the convergence happening in healthcare technology, genomics company GuardantHealth is teaming with health IT and analytics vendor Flatiron Health to create a new platform to enable personalized cancer care.
How does personalized medicine fit into the future of healthcare?
While advances in care will extend the life of people, the impact of this shift on society may be dramatic.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Precision Medicine: 8 must-follow Twitter users (updated)
While it's challenging to keep up to date with all the news in precision medicine, Twitter's a good place to get a constant stream of good information - if you know where to look. These Twitter users know a thing or two about precision medicine.
Allscripts invests $200M in Soon-Shiong’s NantHealth in software integration deal (updated)
In a joint press release, NantHealth and Allscripts said that they would jointly integrate their software via application provider interfaces
Eric Topol: Frustrated that doctors are slow to adopt pharmacogenomics
"We basically have a medical community that doesn't embrace the use of genomics," Dr. Eric Topol said. "Often times these days, it's the patients that are clamoring."
‘Internet of Me,” outcomes headline Accenture health IT trends (infographic)
Accenture has come out with its annual list of trends in health IT, and it's safe to say the research and consulting firm is looking far beyond Meaningful Use.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Soon-Shiong discusses ’empowered’ care, NantHealth’s new product (audio)
As we reported earlier, Dr. Patrick Soon-Shiong keynoted at the American Telemedicine Association’s annual meeting this past week. I also got a chance to meet with him for just a few minutes after his talk, and recorded the interview. In this recording, Soon-Shiong, the billionaire founder of NantWorks and NantHealth, expressed the belief that patients need to be more […]
Obama proposes Medicare officials be allowed to negotiate prices with drug manufacturers
President Obama proposes that drug manufacturers and Medicare officials work together on drug prices to make precision medicine a more realistic option for beneficiaries.
Personalized medicine’s potential grows. But what signals real progress?
Is it the president's new initiative? The big investments out of JP Morgan? Or, most recently, the breakthrough decision by the FDA around 23andMe and other genetic testing kits. It's not about whether personalized medicine has arrived. It's here. Now it's about not getting lost in the hype and focusing on what matters.
FDA decision allows 23andMe back in genetic testing business (but it means so much more)
23andMe can offer genetic-testing services again after the U.S. Food and Drug Administration said the California company can sell a kit to test for Bloom Syndrome, an obscure affliction that occurs when the altered gene is carried by both patents. This is a crack-in-the-dam moment – not just for 23andMe, which has been out of […]
Barack Obama’s precision medicine plan a $215M publicity play – and that’s A-OK.
What’s the best thing about Obama’s new, $215 million precision medicine initiative? While a database of genomic and phenotypic data is great, it’s really all about buzz that could be transformative for biological research – and for business. Just like the 2013 BRAIN Initiative worth $100 million (a scant sum, really, when it comes to […]